Peptide medicines are expanding rapidly across global pharmaceutical markets, while

European demand for specialist and personalised formulations continues to develop. For Dutch compound pharmacies, the opportunity is to build greater flexibility into their API sourcing without adding unnecessary complexity to procurement.

Local access can be a competitive advantage.

The Netherlands is already a pharmaceutical powerhouse

The Netherlands may be a relatively small market by population, but its pharmaceutical infrastructure is significant.

The country is home to a strong life sciences and health ecosystem, supported by pharmaceutical manufacturing, biotechnology, clinical research and one of Europe’s most developed logistics networks.

The Dutch pharmaceutical market was worth around €7.5 billion in 2024, while the country’s life sciences and health sector continues to attract substantial international investment.

The Netherlands also has an important role in European pharmaceutical distribution.

Its ports, airports and logistics infrastructure make the country a major gateway into the wider European market. For compound pharmacies, that broader ecosystem supports access to specialist pharmaceutical products and APIs from across the EU and beyond.

But logistics alone are not enough.

When dealing with technically demanding ingredients such as peptides, the quality of the sourcing relationship matters just as much as delivery speed.

Peptides are becoming a bigger part of pharmaceutical development

The commercial momentum behind peptides is well established.

GLP-1 medicines have transformed the metabolic health market, while peptide development continues across endocrinology, oncology, reproductive health and other specialist areas.

The European Medicines Agency has also introduced more detailed guidance around the development and manufacture of synthetic peptides, reflecting the growing importance of this class of active substances within pharmaceutical development.

For Dutch compound pharmacies, this creates an opportunity to think about peptides as part of a broader specialist API strategy rather than a single-product trend.

The ability to source GMP peptide APIs efficiently can support a more responsive formulation operation.

Why proximity matters in API procurement

International API sourcing can introduce multiple variables.

Manufacturing location, export procedures, freight, customs, documentation and delivery times can all influence the procurement process.

An EU-based supplier can simplify part of that equation.

Working with a supplier located within the Netherlands gives Dutch compound pharmacies a more accessible point of contact for specialist API procurement, while still providing access to an international manufacturing network.

That can be particularly valuable for smaller procurement teams.

Instead of dealing directly with multiple overseas manufacturers, a compound pharmacy can work through a specialist distributor that understands pharmaceutical sourcing and can coordinate the relevant supply-chain requirements.

The result is a more efficient procurement model.

GMP gives local sourcing greater value

Proximity only matters if the underlying API quality is right.

For specialist peptides, GMP sourcing provides an important foundation.

GMP manufacturing establishes controlled processes around production, quality management, testing and documentation. For compound pharmacies, sourcing APIs through qualified GMP manufacturers can help support consistent incoming-material controls and a more predictable formulation process.

This is particularly relevant when working with peptides because their quality profile can require detailed analytical assessment.

Identity, purity, related substances and other critical quality attributes need to be appropriately controlled. A compound pharmacy therefore benefits from a supplier that can provide the technical information required to assess and manage the API.

Local supplier access and GMP sourcing can work together.

One provides procurement efficiency.

The other provides the quality foundation.

Supply resilience starts with options

The pharmaceutical industry has learned that supply chains cannot always be taken for granted.

The European Commission has identified shortages of critical medicines as a strategic concern and has been developing measures to strengthen the resilience of pharmaceutical supply chains across the EU.

For compound pharmacies, supply resilience means having options.

That does not necessarily mean holding large inventories.

It means having established supplier relationships and access to alternative manufacturing sources when a particular API becomes difficult to obtain.

A specialist distributor can play an important role here.

MedicaPharma works with a network of more than 400 GMP manufacturers, giving pharmaceutical customers access to specialist and niche APIs through an established international sourcing network.

For Dutch compound pharmacies, that combines local supplier accessibility with international manufacturing reach.

Procurement efficiency can support formulation flexibility

A compound pharmacy’s ability to respond to a new formulation requirement is partly determined by how quickly it can secure the necessary API.

This is where supplier responsiveness becomes commercially important.

If sourcing a specialist peptide involves multiple international enquiries, uncertain lead times and complicated logistics, a potentially viable formulation can become difficult to execute.

A specialist API supplier can reduce that friction.

Once a compound pharmacy has an established relationship, future sourcing requirements can be assessed through the same procurement channel. New APIs can be investigated, specifications reviewed and manufacturing options evaluated without starting the suppliersearch process from scratch.

That creates greater operational flexibility.

The Dutch market is well positioned for specialist compounding

The Netherlands has a long-standing culture of pharmaceutical innovation and personalised healthcare.

Dutch compound pharmacies operate within a highly developed healthcare system and serve patients whose needs do not always fit a standard commercially manufactured medicine.

That creates a natural role for specialist formulation.

The opportunity for peptide APIs is not about turning every emerging peptide into a compounded preparation. It is about having the sourcing capability to respond when an appropriate formulation requirement exists.

For compounders, that distinction keeps the business focused.

Instead of building speculative inventory, they can develop a flexible supply network that allows them to investigate and source specialist APIs according to genuine demand.

Local expertise, international reach

This is where MedicaPharma’s Dutch base becomes particularly relevant.

A local supplier does not necessarily mean a limited supplier network.

MedicaPharma combines a Netherlands-based operation with access to more than 400 GMP manufacturers internationally, allowing compound pharmacies to benefit from local communication and support while accessing a wider range of specialist API manufacturing capabilities.

For procurement teams, this can simplify supplier management.

For compound pharmacy owners, it can provide a more straightforward route into specialist peptide sourcing.

And for the wider business, it creates an opportunity to build a more agile API strategy without unnecessarily increasing supply-chain complexity.

The advantage is not just faster delivery

The strongest argument for an EU-based peptide API supplier is broader than logistics.

It is about reducing friction across the procurement process.

A Dutch compound pharmacy can work with a supplier operating within the same

European market while still accessing international manufacturing capacity. That can make communication, documentation, ordering and ongoing supplier management more straightforward.

It can also make it easier to establish a long-term procurement relationship.

For specialist APIs, that relationship has real value.

The supplier learns what the compound pharmacy needs, while the compounder gains a more efficient route to future sourcing requirements.

Build your peptide sourcing strategy closer to home

Peptide development is accelerating, and Dutch compound pharmacies have an opportunity to build specialist formulation capabilities around it.

But successful peptide compounding depends on more than finding an ingredient.

It requires reliable API sourcing, qualified manufacturing partners and a supply chain that can support the compounder’s operational requirements.

For Dutch businesses, having access to a specialist supplier based in the Netherlands adds another advantage: proximity without sacrificing international reach.

MedicaPharma combines its Dutch base with a network of more than 400 GMP manufacturers to provide pharmaceutical customers with access to specialist APIs and international sourcing expertise.

If your compound pharmacy is looking to source GMP peptide APIs with a more efficient EU-based supply route, explore the MedicaPharma API portfolio or speak with our team about sourcing your next specialist ingredient.